NIR light‐triggered nanomaterials‐based prodrug activation towards cancer therapy
Citations Over TimeTop 19% of 2020 papers
Abstract
Nanomaterials-based prodrug activation systems have been widely explored in cancer therapy, aiming at overcoming limited dosage formulation, systemic toxicity, and insufficient pharmacokinetic performance of parent drugs. For better delivery control, various stimuli systems, especially nanomaterials-based ones, have come to the forefront. Among them, near-infrared (NIR) light takes advantage of on-demand/site-specific regulation and non-invasiveness. In this review, we will address the developments of nanomaterials-based prodrug over the last decade, the activation mechanisms, and bioapplications under NIR light triggering. The advantages and limitations of NIR-triggered prodrug activation strategies and the perspectives of the next-generation prodrug nanomedicine will also be summarized. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies.
Related Papers
- → Prodrugs to Codrugs(2017)3 cited
- → Concept of Prodrug(2015)1 cited
- → The dinitrobenzamide mustard prodrugs, PR-104A and SN27686, for use in a novel MNDEPT cancer prodrug therapy approach(2023)1 cited
- The progress of antitumor prodrug in target tumor therapy(2007)
- → Use of prodrugs in cancer therapy - A Review(2020)